Cargando…

Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy

Detalles Bibliográficos
Autores principales:	Landfeldt, Erik, Lochmüller, Hanns, Lindgren, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446357/ https://www.ncbi.nlm.nih.gov/pubmed/30940156 http://dx.doi.org/10.1186/s13023-018-0975-3

Ejemplares similares

Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
por: Landfeldt, Erik, et al.
Publicado: (2016)

Quantifying the burden of caregiving in Duchenne muscular dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2016)

Compliance to Care Guidelines for Duchenne Muscular Dystrophy
por: Landfeldt, Erik, et al.
Publicado: (2015)

The burden of Duchenne muscular dystrophy: An international, cross-sectional study
por: Landfeldt, Erik, et al.
Publicado: (2014)

Health‐related quality of life in patients with Duchenne muscular dystrophy: a multinational, cross‐sectional study
por: Landfeldt, Erik, et al.
Publicado: (2015)

Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
por: Landfeldt, Erik, et al.
Publicado: (2020)

Extending Life in Duchenne Muscular Dystrophy: Implications for Appraisals of Cost-Effectiveness
por: Landfeldt, Erik
Publicado: (2018)

Transition from childhood to adulthood in Duchenne muscular dystrophy (DMD)
por: Rodger, Sunil, et al.
Publicado: (2012)

Effect of Yoga and Ayurveda on Duchenne Muscular Dystrophy
por: Telles, Shirley, et al.
Publicado: (2011)

Duchenne muscular dystrophy: Advances in molecular appraoch
por: Benitto, Afaf, et al.
Publicado: (2013)

Adult care for Duchenne muscular dystrophy in the UK
por: Rodger, Sunil, et al.
Publicado: (2014)

Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis
por: Ferizovic, Nermina, et al.
Publicado: (2022)

Comparative proteomic analyses of Duchenne muscular dystrophy and Becker muscular dystrophy muscles: changes contributing to preserve muscle function in Becker muscular dystrophy patients
por: Capitanio, Daniele, et al.
Publicado: (2020)

Blood-derived biomarkers correlate with clinical progression in Duchenne muscular dystrophy
por: Strandberg, Kristin, et al.
Publicado: (2020)

Celiac Disease in a Boy with Duchenne Muscular Dystrophy: A Double Jeopardy!
por: Sharawat, Indar K., et al.
Publicado: (2020)

A classical phenotype of Duchenne muscular dystrophy in a girl with X; autosome translocation
por: Uzunhan, Tuğce Aksu, et al.
Publicado: (2014)

Combination of regional anaesthetic techniques in a Duchenne Muscular Dystrophy carrier undergoing mastectomy
por: Rathi, Raksha, et al.
Publicado: (2021)

Biomarkers of Duchenne muscular dystrophy: current findings
por: Szigyarto, Cristina Al-Khalili, et al.
Publicado: (2018)

Current Pharmacological Strategies for Duchenne Muscular Dystrophy
por: Yao, Shanshan, et al.
Publicado: (2021)

Tracking disease progression non‐invasively in Duchenne and Becker muscular dystrophies
por: Spitali, Pietro, et al.
Publicado: (2018)

Measuring What Matters: Little Evidence Supporting the Content Validity of EQ-5D in People with Duchenne Muscular Dystrophy and Their Caregivers
por: Powell, Philip A., et al.
Publicado: (2021)

Early prophylaxis of cardiomyopathy with beta-blockers and angiotensin receptor blockers in patients with Duchenne muscular dystrophy
por: Lee, Heirim, et al.
Publicado: (2022)

Spontaneous Coronary Artery Dissection in the Setting of Duchenne Muscular Dystrophy: More Questions Than Answers
por: Yalta, Kenan, et al.
Publicado: (2023)

Cardiomyopathy in Duchenne Muscular Dystrophy: A Single-Center Experience
por: Kummitha, Karthikeyan, et al.
Publicado: (2022)

Current and emerging treatment strategies for Duchenne muscular dystrophy
por: Mah, Jean K
Publicado: (2016)

Duchenne and Becker muscular dystrophy in adolescents: current perspectives
por: Andrews, Jennifer G, et al.
Publicado: (2018)

Costs of Illness of Spinal Muscular Atrophy: A Systematic Review
por: Landfeldt, Erik, et al.
Publicado: (2021)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Longitudinal serum biomarker screening identifies malate dehydrogenase 2 as candidate prognostic biomarker for Duchenne muscular dystrophy
por: Signorelli, Mirko, et al.
Publicado: (2019)

Current Translational Research and Murine Models For Duchenne Muscular Dystrophy
por: Rodrigues, Merryl, et al.
Publicado: (2016)

Current care practices for patients with Duchenne muscular dystrophy in China
por: Zhang, Shu, et al.
Publicado: (2022)

Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy
por: Eser, Gökçe, et al.
Publicado: (2022)

Biomarkers in Duchenne Muscular Dystrophy: Current Status and Future Directions
por: Fortunato, Fernanda, et al.
Publicado: (2023)

Association of Autism Spectrum Disorder with Pre-symptomatic Duchenne Muscular Dystrophy: Isolated Elevation of Transaminases as a Diagnostic Clue
por: Panda, Prateek K., et al.
Publicado: (2021)

Detection of the mutation may guide treatment of heart and muscle in Duchenne muscular dystrophy
por: Finsterer, Josef, et al.
Publicado: (2016)

Drug treatment of Duchenne muscular dystrophy: available evidence and perspectives
por: DE LOS ANGELES BEYTÍA, MARIA, et al.
Publicado: (2012)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_eqt3o8j0mbfc8ua3mq5qh03c7l